Actively Recruiting
Randomized Trial of Oral NPI-001 Versus Placebo for Preserving Photoreceptors in Adults With Retinitis Pigmentosa and Usher Syndrome Over 24 Months
Led by Nacuity Pharmaceuticals, Inc. · Updated on 2026-10-13
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether NPI-001 can slow the progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. This clinical trial will also assess the safety of NPI-001 by comparing it to a placebo. The main goals are to determine if NPI-001 preserves photoreceptors and to monitor any medical problems participants may experience while taking the drug. Participants will take either NPI-001 or a placebo tablet orally twice a day for 24 months. The study follows a randomized, double-masked design with two groups one receiving the active drug N-acetyl cysteine amide 250 mg twice daily and the other receiving a placebo. Over the course of the study, participants will attend nine clinic visits for checkups and tests. During the trial, participants will undergo assessments including measuring the ellipsoid zone area to evaluate photoreceptor preservation. Researchers will monitor safety and efficacy throughout the 24 months of treatment. The study is sponsored by Nacuity Pharmaceuticals, Inc. and aims to provide detailed information about the effect of NPI-001 on vision preservation in this patient population.
CONDITIONS
Brief Title
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Research Team
N
Nacuity Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here